Literature DB >> 20855850

3-Methylglutaconic aciduria type I redefined: a syndrome with late-onset leukoencephalopathy.

S B Wortmann1, B H Kremer, A Graham, M A Willemsen, F J Loupatty, S L Hogg, U F Engelke, L A Kluijtmans, R J Wanders, S Illsinger, B Wilcken, J R Cruysberg, A M Das, E Morava, R A Wevers.   

Abstract

OBJECTIVE: 3-Methylglutaconic aciduria type I is a rare inborn error of leucine catabolism. It is thought to present in childhood with nonspecific symptoms; it was even speculated to be a nondisease. The natural course of disease is unknown.
METHODS: This is a study on 10 patients with 3-methylglutaconic aciduria type I. We present the clinical, neuroradiologic, biochemical, and genetic details on 2 new adult-onset patients and follow-up data on 2 patients from the literature.
RESULTS: Two unrelated patients with the characteristic biochemical findings of 3- methylglutaconic aciduria type I presented in adulthood with progressive ataxia. One patient additionally had optic atrophy, the other spasticity and dementia. Three novel mutations were found in conserved regions of the AUH gene. In both patients, MRI revealed extensive white matter disease. Follow-up MRI in a 10-year-old boy, who presented earlier with isolated febrile seizures, showed mild abnormalities in deep white matter.
CONCLUSION: We define 3-methylglutaconic aciduria type I as an inborn error of metabolism with slowly progressive leukoencephalopathy clinically presenting in adulthood. In contrast to the nonspecific findings in pediatric cases, the clinical and neuroradiologic pattern in adult patients is highly characteristic. White matter abnormalities may already develop in the first decades of life. The variable features found in affected children may be coincidental. Long-term follow-up in children is essential to learn more about the natural course of this presumably slowly progressive disease. Dietary treatment with leucine restriction may be considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855850     DOI: 10.1212/WNL.0b013e3181f39a8a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  [Newborn screening as a predictive genetic test: principles and challenges].

Authors:  Johannes Zschocke
Journal:  Wien Med Wochenschr       Date:  2012-03-28

2.  Expanded newborn screening: reducing harm, assessing benefit.

Authors:  Bridget Wilcken
Journal:  J Inherit Metab Dis       Date:  2010-05-04       Impact factor: 4.982

3.  Experimental Evidence that 3-Methylglutaric Acid Disturbs Mitochondrial Function and Induced Oxidative Stress in Rat Brain Synaptosomes: New Converging Mechanisms.

Authors:  Ana Laura Colín-González; Ariana Lizbeth Paz-Loyola; María Eduarda de Lima; Sonia Galván-Arzate; Bianca Seminotti; César Augusto João Ribeiro; Guilhian Leipnitz; Diogo Onofre Souza; Moacir Wajner; Abel Santamaría
Journal:  Neurochem Res       Date:  2016-06-09       Impact factor: 3.996

4.  A review of the diverse genetic disorders in the Lebanese population: highlighting the urgency for community genetic services.

Authors:  Ghunwa Nakouzi; Khalil Kreidieh; Soha Yazbek
Journal:  J Community Genet       Date:  2014-09-27

5.  Bezafibrate In Vivo Administration Prevents 3-Methylglutaric Acid-Induced Impairment of Redox Status, Mitochondrial Biogenesis, and Neural Injury in Brain of Developing Rats.

Authors:  Nevton Teixeira da Rosa-Junior; Belisa Parmeggiani; Mateus Struecker da Rosa; Nícolas Manzke Glänzel; Leonardo de Moura Alvorcem; Moacir Wajner; Guilhian Leipnitz
Journal:  Neurotox Res       Date:  2019-03-09       Impact factor: 3.911

Review 6.  Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature.

Authors:  Saskia B Wortmann; Marinus Duran; Yair Anikster; Peter G Barth; Wolfgang Sperl; Johannes Zschocke; Eva Morava; Ron A Wevers
Journal:  J Inherit Metab Dis       Date:  2013-01-08       Impact factor: 4.982

Review 7.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

8.  The Expanding MEGDEL Phenotype: Optic Nerve Atrophy, Microcephaly, and Myoclonic Epilepsy in a Child with SERAC1 Mutations.

Authors:  Heidi S Lumish; Yaping Yang; Fan Xia; Ashley Wilson; Wendy K Chung
Journal:  JIMD Rep       Date:  2014-07-06

9.  3-Methylglutaconic aciduria--lessons from 50 genes and 977 patients.

Authors:  Saskia B Wortmann; Leo A J Kluijtmans; Richard J Rodenburg; Jörn Oliver Sass; Jessica Nouws; Edwin P van Kaauwen; Tjitske Kleefstra; Lisbeth Tranebjaerg; Maaike C de Vries; Pirjo Isohanni; Katharina Walter; Fowzan S Alkuraya; Izelle Smuts; Carolus J Reinecke; Francois H van der Westhuizen; David Thorburn; Jan A M Smeitink; Eva Morava; Ron A Wevers
Journal:  J Inherit Metab Dis       Date:  2013-01-25       Impact factor: 4.982

Review 10.  Contemporary scope of inborn errors of metabolism involving epilepsy or seizures.

Authors:  Birutė Tumienė; Borut Peterlin; Aleš Maver; Algirdas Utkus
Journal:  Metab Brain Dis       Date:  2018-07-13       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.